About Genomic Health 
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that help optimize cancer care by addressing the overtreatment of the disease, one of the greatest issues in healthcare today. With its Oncotype IQ® Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company's flagship line of Oncotype DX gene expression tests that have been used to guide treatment decisions for more than 750,000 cancer patients worldwide. Genomic Health is expanding its test portfolio to include additional liquid- and tissue-based tests, including the recently launched Oncotype SEQ® Liquid Select™ test. The company is based in Redwood City, California, with international headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth,  Facebook, YouTube and LinkedIn.

About Oncotype DX®
The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. The company's flagship product, the Oncotype DX Breast Recurrence Score®, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. Additionally, the Oncotype DX Breast DCIS Score™ predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS. In prostate cancer, the Oncotype DX Genomic Prostate Score™ predicts disease aggressiveness and further clarifies the current and future risk of the cancer prior to treatment intervention. With more than 750,000 patients tested in more than 90 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.OncotypeIQ.com, www.MyBreastCancerTreatment.org or www.MyProstateCancerTreatment.org.

Invitae

Genomic Health

Cancer, whether it be breast cancer or another form, touches just about everyone, including Kim Popovits, Chairman, CEO and President at Genomic Health, Inc. Ms. Popovits talks about her inspiration for getting involved with personalized medicine in the treatment of cancer. https://lnkd.in/eyvQx_2

My Prostate Cancer Coach

My Cancer Coach

PCa Risk

Genomic Health Mobile

My Breast Cancer Coach

Cancer Coach

Prostate Cancer Clinical Risk Classification Tool

IPhone / Mobile Compatible

Viewport Meta

Domain Not Resolving

SSL by Default

Google Tag Manager

HSTS

DNSSEC

Content Delivery Network

Amazon

Chariman of the Board, Chief Executive Officer & President

Kimberly Popovits

Finance and Administration

Brian Hogan

Business Management

Christer Svedman

Engineering

Clement Yu

Director, Facilities Services

David Quinn

Operations

Eric Strom

Greg Morimoto

Director of Systems Engineering

Hubert Yeung

Marketing and Product

Jennifer Policky

Director, New Product Operations

Kenneth Hoyt

Samuel Colella

Ginger Graham

Henry J. Fuchs

G. Bradley Cole

Dean L. Schorno

Venora Hung

Privacy Counsel

Kimberly J. Popovits

President, CEO & Chairman

rick baehner

Vice President Medical Oncology and Pathology

Invitae is a medical genetics company that bring comprehensive genetic information into mainstream medicine to improve healthcare.

California Acquired Companies (Top 10K)

Silicon Valley Companies With More Than 10 Employees (Top 10K)

Acquired West Coast Companies (Top 10K)

Pharmaceutical Acquired Companies With Fewer Than 1000 Employees

Genomic Health, Inc. (NASDAQ: GHDX) is a provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California, with European headquarters in Geneva, Switzerland.

Medical and Beauty Services and Agricultural Services

Redwood City

California

United States

North America

Prostate Cancer Diagnostics Market Insights, Competitive Landscape, and Forecasts, 2030 - Advancements and Increased Awareness to Propel Growth

Genomic Health slapped with $32M hit over cancer testing practices

Exact Sciences stock jumps on cancer detection deals for Thrive, Base Genomics

Exact Sciences Boosting Position in Cancer Dx Market Through M&A

Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company

Shenandoah Telecommunications Set to Join S&P SmallCap 600

Genomic Health, Inc. (GHDX): Hedge Funds Cashed Out Too Early

Gencurix's Study Explores the Difference between GenesWell BCT and Oncotype DX

New Publication Shows Different Result of Risk Classification between GenesWell BCT and Oncotype DX in Breast Cancer Patients 50 Years Old or Younger.

URGENT: Monteverde & Associates PC is Investigating the Following Transaction

A genomic test that helps assess the risk of breast cancer recurrence and informs treatment decisions for patients with early-stage ER+/HER2- breast cancer.

A test that identifies hereditary genetic changes associated with increased cancer risk, aiding in personalized prevention and treatment strategies.

A comprehensive genomic profiling test that helps identify targeted therapy options for patients with advanced or metastatic cancer.

An upcoming version of the Cologuard test designed to enhance colorectal cancer screening performance while maintaining at-home testing convenience.

A genomic test under development to determine the necessity of radiation therapy for women with early-stage breast cancer post-surgery.

A blood-based screening method for colorectal cancer, aimed at expanding screening options for a broader population.

India

Asia

Cambodia

.NET 4.5

Office 365

Google Fonts

Google Analytics

Modernizr

jQuery

Facebook Comments

GoDaddy

Amazon Route 53

A company specializing in cancer detection and diagnostics

Exact Sciences Corporation

Provider of genomic profiling tests for cancer patients

Foundation Medicine

Company focused on molecular diagnostics and personalized medicine

Myriad Genetics

Genomic Health, Inc. was a company focusing on genetic research specifically in cancer detection, based out of Redwood City, California. The company developed Oncotype DX, a genomic assay that quantified the likelihood of breast cancer recurrence.

news impact assignment basic	general	Feb 15, 2024 5:58 PM	6dd85613
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Dec 4, 2024 8:54 AM	39cc5a7b
crunchbase profile	general	Dec 4, 2024 12:44 PM	8de79b38
li profile	general	Feb 15, 2024 5:58 PM	6bdff547
translate crunchbase fundingrounds	general	Dec 4, 2024 1:38 PM	aa8dc04b
peers	general	Feb 15, 2024 5:58 PM	582eace1
news basic	general	Feb 15, 2024 5:58 PM	97427cbd
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:GENOMICHEALTH

Genomic Health, Inc.